Text Size:AAA

IL2Ra / CD25 抗體, 兔多抗

產品資料評論實驗方法
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10165-H02H-50
10165-H02H-100
50 µg 
100 µg 
Add to Cart
描述: Active  
表達宿主: Human Cells  
  • Slide 1
10165-H08H-50
10165-H08H-20
50 µg 
20 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
50292-M08H-50
50292-M08H-100
50 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
90265-CCCH-5
90265-CCCH-20
90265-CCCH-100
5 µg 
20 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
90265-C08H-50
90265-C08H-100
50 µg 
100 µg 
Add to Cart
表達宿主: Human Cells  
  • Slide 1
90265-C02H-50
90265-C02H-100
50 µg 
100 µg 
Add to Cart

IL2RA/IL-2RA/CD25 AntibodyRelated Products

Related Products

Featured Reagent Products

IL2RA/IL-2RA/CD25 antibody 研究背景

CD25 (alpha-chain of IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development is associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of sIL-2Ralpha. In most haematological malignancies, including different types of leukaemias and lymphomas, sIL-2Ralpha has been found to be released directly from the surface of neoplastic cells thus reflecting the tumour bulk, turnover and activity. Several studies have proved that not only lymphoid cancer cells, but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, oesophagus and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and in many solid tumors.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

 IL2RA/IL-2RA/CD25 antibody 參考資料
  • Driesen J, et al. (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 213(9-10): 849-58.
  • Olejniczak K, et al. (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med Sci Monit. 14(10): RA179-89.
  • Chistiakov DA, et al. (2008) The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 118(1): 1-5.
  • Bien E, et al. (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 13(1): 1-26.
  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”